Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Dec 08, 2022 11:47am
132 Views
Post# 35159279

RE:RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame management

RE:RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame managementThe problem with chemo drugs like docetaxel, doxorubicin or SN38, is that you need selective cleavage of the linker inside the cells. That means part of it will cleave outside the cells, in the bloodstream. One of the big advantage of radioisotopes, is that cleavage from linker is not needed, in fact, it needs to be completely avoided. All you need is PDC bonding with the receptor and internalization. If TH19P01 can do that, this part of the concept works. The other part of the concept would be related to sortilin expression throughout the human body and tumors. What is the distribution of sortilin within the human body and how much of the PDC is it catching? This is key for toxicity and Ga68 would allow to measure that. Ga68 could also allow to select only the right patient that are overexpressing enough sortilin on the cancer cells.

LouisW wrote: Maybe SN38 is doable? I guess they already have some data.

jfm1330 wrote:
TH1902 TH19P01

PDC Aeterna Zentaris PDCAEZS-108 Zoptrex PDC Thera Ib  

TH1902 TH19P01 “”

PDC PDC ADC Lutathera PluvictoLu177-Dotatate Lu177-PSMA Lu177 DOTA Pluvicto

“”Thera TH19P01 DOTA TH19P01 Lu177 Ga68 Ga68 “” Ga68 Lu177 I

Ga68 Lu177 Lu177

TH19P01 DOTA-Lu177 DOTA-Ga68 ADC



<< Previous
Bullboard Posts
Next >>